MyProstateScore 2.0 Clinically Validated in New JAMA Oncology Study
ANN ARBOR, Mich., April 18, 2024 /PRNewswire/ -- Lynx Dx, a leader in innovative diagnostic solutions, hailed new peer-reviewed research published today in the Journal of the American Medical Association (JAMA) Oncology that validates the efficacy of MyProstateScore 2.0 (MPS2), the company's groundbreaking prostate cancer risk assessment test. The findings signify a major advancement in the ability to make highly accurate, comprehensive and personalized predictions by raising the performance standard for urine biomarker tests intended to detect clinically significant prostate cancer.
- Further, more than 75% of men with an elevated PSA will have a biopsy negative for clinically significant cancer.
- In the clinical validation of MPS2 published in JAMA Oncology, scientists evaluated whether MPS2 could improve prostate cancer screening outcomes relative to existing biomarkers.
- Key findings from the paper include:
MPS2 was clinically validated separately in patients presenting for initial biopsy (i.e., biopsy naïve) and those presenting for a repeat biopsy (i.e., prior negative biopsy). - Paper cited: "Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer," JAMA Oncology.